Oppenheimer Sticks to Its Hold Rating for Fate Therapeutics (FATE)

In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Hold rating on Fate Therapeutics (FATE – Research Report). The company’s shares closed yesterday at $1.00.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences. According to TipRanks, Biegler has an average return of -15.7% and a 28.35% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fate Therapeutics with a $6.17 average price target.

The company has a one-year high of $5.92 and a one-year low of $0.66. Currently, Fate Therapeutics has an average volume of 2.49M.